Halberd Pre-Clinical Test Protocol Approved

Rhea-AI Summary

Halberd Corporation is set to begin testing a nasal spray designed to counteract the effects of head trauma. The study aims to limit the presence of excess neurotransmitters and decrease hypermetabolism. The goal is to conclude the study within six months.

Positive

• Halberd Corporation is starting testing of a nasal spray to counteract the effects of head trauma. The study aims to limit the presence of excess neurotransmitters and decrease hypermetabolism, potentially leading to positive outcomes. This represents an expansion of Halberd's methodology and provides additional intellectual property opportunities.

Negative

• None.

Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month's End

JACKSON CENTER, PA / ACCESSWIRE / May 9, 2023 / Halberd Corporation (OTC PINK:HALB) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering will begin as early as next week.

Medical literature indicates that a pathophysiologic connection exists between various excess neurotransmitters and certain neurodegenerative diseases. Halberd's study aims to establish positive outcomes through limiting the presence of excess neurotransmitters through its patent-pending triple-action nasal spray containing ingredients to prevent inflammation and swelling, inhibit generation of excess excitatory neurotransmitters, and decrease hypermetabolism.

This nasal spray technology represents an expansion of Halberd's extracorporeal methodology in treating medical conditions through a preventative approach and provides additional intellectual property opportunities, an avenue for developing research contracts/grants and future revenue streams.

The goal is to conclude the study within six months.

To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2023, Halberd Corporation

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/753622/Halberd-Pre-Clinical-Test-Protocol-Approved

FAQ

What is Halberd Corporation testing?

Halberd Corporation is testing a nasal spray designed to counteract the effects of head trauma.

What is the goal of the study?

The goal of the study is to limit the presence of excess neurotransmitters and decrease hypermetabolism.

How long is the study expected to take?

The study is expected to conclude within six months.

What are the potential outcomes of the study?

The study aims to establish positive outcomes by limiting excess neurotransmitters, potentially leading to improved treatment for head trauma.

What opportunities does this nasal spray technology provide for Halberd Corporation?

This nasal spray technology provides additional intellectual property opportunities and potential revenue streams for Halberd Corporation.